Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow JAZZ
Jazz Pharmaceuticals PLC (JAZZ) EV/Sales
As of 16 October 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from 2.2× (May 2025) to 10.2× (March 2015); the current reading is higher than 26% of that period. That is below the Biotechnology industry median of 9.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | 18.02% |
| FY2024 | 2.6× | (16.57%) |
| FY2023 | 3.2× | (20.89%) |
| FY2022 | 4.0× | (5.36%) |
| FY2021 | 4.2× | 8.97% |
| FY2020 | 3.9× | (6.95%) |
| FY2019 | 4.2× | (4.06%) |
| FY2018 | 4.3× | (23.86%) |
| FY2017 | 5.7× | 1.61% |
| FY2016 | 5.6× | (15.61%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.8× | 18.22% |
| Mar 2026 | 3.2× | 2.65% |
| Dec 2025 | 3.1× | 14.37% |
| Sep 2025 | 2.7× | 9.15% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| EXEL Exelixis, Inc. compare | 6.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. compare | 9.7× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| BBIO BridgeBio Pharma, Inc. compare | 19.9× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)